In RET-mutation-positive patients, screening for pheochromocytoma, including annual plasma metanephrines and normetanephrines, or 24-h urine collection for metanephrines and normetanephrines, begins by 8 years of age in carriers of the RET mutation associated with MEN 2b and codons 630 and 634, and by 20 years of age in carriers of other MEN 2a RET mutations. The gene discussed is RET; the disease is multiple endocrine neoplasia.